These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33201745)

  • 1. Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring.
    Ho SA; Slavin M; Roberts JA; Yong M
    Expert Rev Anti Infect Ther; 2021 Jun; 19(6):707-718. PubMed ID: 33201745
    [No Abstract]   [Full Text] [Related]  

  • 2. Does therapeutic drug monitoring (TDM) of trough concentrations suffice for optimizing preemptive therapy with ganciclovir of cytomegalovirus infections in non-renal solid organ transplant recipients?
    Gatti M; Rinaldi M; Potena L; Salvaterra E; Morelli MC; Giannella M; Viale P; Pea F
    Transpl Infect Dis; 2023 Oct; 25(5):e14107. PubMed ID: 37515787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring.
    Li QY; van den Anker J; Wu YE; Hao GX; Zhao W
    Expert Rev Clin Pharmacol; 2023; 16(8):727-739. PubMed ID: 36794592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valganciclovir: therapeutic role in pediatric solid organ transplant recipients.
    Yu MA; Park JM
    Expert Opin Pharmacother; 2013 Apr; 14(6):807-15. PubMed ID: 23469871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
    Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.
    Freeman RB
    Expert Opin Pharmacother; 2004 Sep; 5(9):2007-16. PubMed ID: 15330737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial.
    Boeckh M; Nichols WG; Chemaly RF; Papanicolaou GA; Wingard JR; Xie H; Syrjala KL; Flowers ME; Stevens-Ayers T; Jerome KR; Leisenring W
    Ann Intern Med; 2015 Jan; 162(1):1-10. PubMed ID: 25560711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.
    Tängdén T; Cojutti PG; Roberts JA; Pea F
    Clin Pharmacokinet; 2018 Nov; 57(11):1399-1405. PubMed ID: 29546589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.
    Asberg A; Rollag H; Hartmann A
    Expert Opin Pharmacother; 2010 May; 11(7):1159-66. PubMed ID: 20367273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child.
    Autmizguine J; Théôret Y; Launay E; Duval M; Rousseau C; Tapiéro B; Boivin G; Ovetchkine P
    J Popul Ther Clin Pharmacol; 2011; 18(2):e257-60. PubMed ID: 21576729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.
    Razonable RR; Paya CV
    Expert Rev Anti Infect Ther; 2004 Feb; 2(1):27-41. PubMed ID: 15482169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
    Kiser TH; Fish DN; Zamora MR
    J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence supporting the use of therapeutic drug monitoring of ganciclovir in transplantation.
    Wong DD; Ho SA; Domazetovska A; Yong MK; Rawlinson WD
    Curr Opin Infect Dis; 2023 Dec; 36(6):505-513. PubMed ID: 37729654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
    Cochrane AB
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic stem cell transplant cytomegalovirus infection.
    Saleh AJ; Al Mohareb F; Al Rabiah F; Chaudhri N; Al Sharif F; Al Zahrani H; Mohamed SY; Patel M; Rasheed W; Nurgat Z; Bakr M; Ahmed S; Zaidi S; Nasser A; Ibrahim K; Al Abdely H; Aljurf M
    Hematol Oncol Stem Cell Ther; 2010; 3(3):116-20. PubMed ID: 20890068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I; Len O; de la Cámara R; Gurguí M; Martino R; Jarque I; Barrenetxea C; Díaz de Heredia C; Batlle M; Rovira M; de la Torre J; Torres A; Aguilar M; Espigado I; Martín-Dávila P; Bou G; Borrell N; Aguado JM; Pahissa A;
    Antivir Ther; 2011; 16(7):951-7. PubMed ID: 22024510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.